Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM5A | P29375 | 2/20 | 0.55 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.55 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.55 |
| ▸ | KDM6B | O15054 | 1/20 | 0.55 |
| ▸ | TET3 | O43151 | 1/20 | 0.55 |
| ▸ | KDM4A | O75164 | 1/20 | 0.55 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.55 |
| ▸ | KDM5C | P41229 | 1/20 | 0.55 |
| ▸ | ASPH | Q12797 | 1/20 | 0.55 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.55 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.55 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.55 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.55 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.55 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.55 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.55 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30281240 | 1.00 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTKDM5AKDM4C | |
| Hydrochloric Acid SCHEMBL968208 | 0.98 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTKDM5AKDM4C | |
| SCHEMBL4863083 | 0.85 | ALDH1A1 (0.52) | ALDH1A1KDM4EMAPTKDM5AKDM4C | |
| SCHEMBL6173009 | 0.85 | SMYD3 (0.51) | ALDH1A1KDM4EMAPTKDM5AKDM4C | |
| Hydrochloric Acid SCHEMBL971588 | 0.84 | ALDH1A1 (0.50) | ALDH1A1KDM4EMAPTKDM5AKDM4C | |
| SCHEMBL2677778 | 0.83 | SMYD3 (0.54) | ALDH1A1MAPTSMYD3NOS3NOS1 | |
| SCHEMBL743017 | 0.82 | KDM4E (0.57) | ALDH1A1KDM4EMAPTKDM5AKDM4C | |
| SCHEMBL30112054 | 0.82 | KDM4E (0.57) | ALDH1A1KDM4EMAPTKDM5AKDM4C | |
| SCHEMBL4294721 | 0.82 | ALDH1A1 (0.59) | ALDH1A1KDM4EMAPTKDM5AKDM4C | |
| Lithium Ion SCHEMBL21633063 | 0.81 | SMYD3 (0.49) | ALDH1A1KDM4EMAPTKDM5AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114163422-B | Ratio type fluorescent probe for detecting acidic pH value and preparation method and application thereof | 南京林业大学 | 2023-08-18 | — | — | CN | claimed |
| CN-114163422-A | Ratio type fluorescent probe for detecting acidic pH value and preparation method and application thereof | 南京林业大学 | 2022-03-11 | — | — | CN | claimed |
| CN-112438253-A | Saliva preserving fluid and preparation method thereof | 武汉吉诺百客医学科技有限公司 | 2021-03-05 | — | — | CN | claimed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4143195-B1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-09-19 | — | — | US | disclosed |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-02 | — | — | US | disclosed |
| CN-112204009-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| CN-115073358-B | Preparation method of N-benzyl-4-ethyl piperidine formate | 安徽德诺医药股份有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-114163422-B | Ratio type fluorescent probe for detecting acidic pH value and preparation method and application thereof | 南京林业大学 | 2023-08-18 | — | — | CN | disclosed |
| US-7132426-B2 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| CN-1829718-A | Fused aryl and heteroaryl derivatives as modulators of metabolism and the prevention and treatment of disorders related thereto | ARENA PHARM INC (US) | 2006-09-06 | — | — | CN | disclosed |
| US-20060142262-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| EP-1644375-A2 | FUSED-ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050059650-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005007658-A2 | FUSED-ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-0053789-B1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITION, USEFUL AS AN ANTI-ALLERGIC AGENT | Tanabe Seiyaku Co., Ltd. (JP) | 1985-03-27 | — | — | EP | disclosed |
| US-4404214-A | 2-Pyridinecarboxamide derivatives compositions containing same and method of using same | TANABE SEIYAKU CO., LTD. (JP) | 1983-09-13 | — | — | US | disclosed |
| EP-0053789-A1 | 2-Pyridinecarboxamide derivative, process for preparing same and pharmaceutical composition, useful as an anti-allergic agent | Tanabe Seiyaku Co., Ltd. (JP) | 1982-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | ALDH1A1 164/4885KDM4E 2583/4885MAPT 3647/4885 |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | ALDH1A1 164/4885KDM4E 2583/4885MAPT 3647/4885 |
| US-20060142262-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | ALDH1A1 210/4885KDM4E 1864/4885MAPT 4217/4885 |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ALDH1A1 3433/4885KDM4E 4646/4885MAPT 3293/4885 |
| US-20050059650-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | ALDH1A1 210/4885KDM4E 1864/4885MAPT 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.